Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína3. fázis

A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo

A legfontosabb adatok

Ki végzi
Minghui Pharmaceutical (Hangzhou) Ltd
Hol
Beijing (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
405 fő, tervezett
Kezdés
2026. aug. 4.
Várható befejezés
2028. okt. 4.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • MH004 1.0% Ointment
  • MH004 Placebo Ointment
A regiszteradat frissítve
2026. augusztus 11.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for teenagers and adults with non-segmental vitiligo on the face. It tests MH004 ointment against a placebo ointment.

Életkor
12 to 75 years
Nem
All sexes can join.
A betegség stádiuma
Non-segmental vitiligo diagnosed by a doctor. Facial patches must cover at least 0.3% of body surface area (BSA), with a F-VASI score of at least 0.3.
Korábbi kezelés
People must stop all vitiligo treatments during the trial. People who ever used a JAK inhibitor for vitiligo cannot join. People who ever had depigmentation therapy (except hydroquinone) or vitiligo surgery on the face cannot join. Waiting periods apply for other treatments, such as 8 weeks for light or laser therapy.

A részvétel fő kizáró okai

  • All facial hairs in the vitiligo patches are white
  • Other types of vitiligo or other skin lightening conditions
  • Active or hidden infections, or a history of cancer
  • Pregnancy or breastfeeding
  • Past or planned organ transplant needing long-term drugs that weaken the immune system

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects aged 12 to 75 years inclusive at the time of signing the Informed Consent Form (ICF), with no restriction on gender
  • Clinically diagnosed with non-segmental vitiligo
  • Prior to study drug administration, participants with vitiligo shall meet the following criteria regarding vitiligo lesion area: Facial lesion area ≥ 0.3% body surface area (BSA), and Facial Vitiligo Area Scoring Index (F-VASI) score ≥ 0.3
  • Agree to discontinue all vitiligo therapeutic medications and interventions from the time of ICF signature until the end of the last study visit. Over-the-counter (OTC) drugs shall not exert therapeutic effects on vitiligo or interfere with skin pigmentation, including corticosteroids and other immunomodulators. Final eligibility of such OTC drugs shall be determined by the Investigator. Camouflaging makeup is permitted
  • Women of Childbearing Potential (WOCBP) and male participants whose partners are WOCBP must agree to use reliable contraceptive methods throughout the trial period and for 28 days after the last study drug administration (abstinence, prior sterilization, oral contraceptives, and/or barrier methods [condoms, diaphragms, cervical caps, etc.]). For WOCBP, the human chorionic gonadotropin (hCG) pregnancy test result at the screening visit and prior to the first drug administration at the baseline visit must be negative. Male participants shall not donate sperm during the trial and for 3 months after study completion or drug discontinuation
  • The participant and/or their legal guardian shall fully understand the trial content, requirements and procedures, voluntarily participate in this clinical trial and sign the ICF, and be willing and able to comply with scheduled visits, treatment regimens, laboratory tests and other study procedures throughout the trial

Ki nem vehet részt

  • Specific prior treatment history:; Prior use of any JAK inhibitor (systemic or topical) for vitiligo treatment at any time; Prior depigmentation therapy for vitiligo (e.g., monobenzone), excluding hydroquinone; Prior melanocyte-keratinocyte transplantation or other surgical procedures for vitiligo on the face
  • Treatments administered within the required washout period; Use of biologic agents within 12 weeks or 5 half-lives (whichever is longer) prior to the first study drug administration; Receipt of laser therapy or any form of phototherapy (including tanning beds) within 8 weeks prior to the first study drug administration; Within 4 weeks prior to the first study drug administration:; Systemic immunomodulators (e.g., corticosteroids, methotrexate, cyclosporine, etc.); Systemic medications that may affect vitiligo (e.g., melanocyte-stimulating agents, tetracyclines, methoxsalen, etc.); Administration of live or live-attenuated vaccines; Oral traditional Chinese medicines for vitiligo within 2 weeks prior to the first study drug administration; Topical agents applied to vitiligo lesions within 1 week prior to the first study drug administration (e.g., corticosteroids, calcineurin inhibitors, PDE4 inhibitors, retinoids, vitamin D3 analogues, or topical Chinese herbal preparations)
  • Temporary tattoos within vitiligo lesions within 30 days before the first dose (excluding vinyl adhesive tattoos), or any permanent tattoos previously placed within vitiligo lesions
  • Concomitant diseases or medical history that may interfere with the study
  • Subjects planning major invasive procedures during the study, or with prior or planned organ transplantation requiring long-term immunosuppressants (e.g., kidney or liver transplantation)
  • Planned administration of live or live-attenuated vaccines during the study period
  • Participation in another interventional drug clinical trial within 3 months or at least 5 half-lives (whichever is longer) prior to randomization; or participation in a medical device clinical trial within 3 months prior to randomization
  • Hypersensitivity and intolerance Known hypersensitivity to the investigational product or any excipient components
  • Other subtypes of vitiligo or hypopigmentary disorders; Segmental vitiligo, unclassified vitiligo, or mixed vitiligo; Other differential diagnoses of vitiligo or other cutaneous hypopigmentary diseases (e.g., piebaldism, pityriasis alba, nevus anemicus, post-inflammatory hypopigmentation, chemical leukoderma, tinea versicolor, etc.)
  • Active or latent infections
  • History of malignancy
  • Other exclusion factors; History of alcohol abuse or substance misuse; Subjects shall avoid intentional excessive sun exposure during the study (e.g., prolonged sunbathing, sun exposure for tanning purposes); Body mass index (BMI) < 16 kg/m² or > 40 kg/m², where BMI = weight (kg) / height² (m²); Any other conditions deemed inappropriate for study participation by the Investigator
  • Clinically significant abnormal laboratory values
  • All terminal hairs (i.e., beard, eyebrows, eyelashes) within facial vitiligo areas are depigmented white
  • Specific risks of cardiovascular and thromboembolic events
  • Positive virology screening results at screening
  • Female subjects who are pregnant or breastfeeding

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 12 és 75 év között vagy?

Helyszínek itt: Kína

  • Peking University People's HospitalBeijing, KínaContact: Ethics CommitteeRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.

A vizsgálat 3 csoportja

  • Double-Masked Period: MH004 1.0% OintmentA vizsgált kezelés

    Participants received MH004 1.0% Ointment topically twice a day (BID) from Day 1 to Week 24 during the Double-Masked Period.

    Kezelés: MH004 1.0% Ointment

  • Double-Masked Period: MH004 PlaceboPlacebo, összehasonlításként

    Participants received MH004 Placebo Ointment topically twice a day (BID) from Day 1 to Week 24 during the Double-Masked Period.

    Kezelés: MH004 Placebo Ointment

  • Extended Treatment Period: MH004 1.0% OintmentA vizsgált kezelés

    Participants received MH004 1.0%Ointment twice a day (BID) from Week 25 to Week 52 during the Extended Treatment Period.

    Kezelés: MH004 1.0% Ointment

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Adolescent and Adult Subjects With Non-segmental Vitiligo
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT07682506: ki vehet részt
A regiszteradat frissítve
2026. augusztus 11.